TRANSFUSION SUPPORT--CORE

输血支持--核心

• 批准号: 3805850
• 负责人: WILLIAM I BENSINGER
• 金额: --
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3805850
• 关键词: antileukocyte isoantibody; biomedical facility; blood donor; bone marrow transplantation; cell mediated cytotoxicity; cytomegalovirus; data collection; histocompatibility; histocompatibility typing; platelet transfusion; plateletpheresis

The success of marrow transplantation is heavily dependent on the transfusion of blood products and is a situation which provides many opportunities for research in transfusion immunology. In Project IX we have described our research proposals for problems of platelet alloimmunization. In Project III we describe our proposals for the utilization of blood products screened for antibody to cytomegalovirus (CMV) as well as an evaluation of leukocyte-depleted blood products for the prevention of CMV. In this core section we are concerned with mechanisms for deriving research information from clinically necessary transfusion support and plasma modification procedures. We ask support only for key personnel for supervision and data entry where we cannot recover costs from charges but where the work is essential to carrying out the proposed research in individual program projects. These areas include establishing and maintaining data bases containing detailed descriptive information on all blood product transfusions and on the course and outcome of all ABO-incompatible transplants requiring plasma modification or marrow red cell depletion.

骨髓移植的成功在很大程度上取决于 输血的血液制品，是一种情况， 输血免疫学研究的许多机会。 在 项目九我们已经描述了我们的研究建议的问题 血小板同种异体免疫 在项目III中，我们描述了 关于使用经筛选的血液制品的建议 巨细胞病毒（CMV）抗体以及 去白细胞的血液制品用于预防CMV。 在 这一核心部分，我们关注的机制， 来自临床必要输血支持的研究信息 和等离子体改性程序。 我们只要求支持关键 我们无法恢复的监督和数据输入人员 费用，但如果工作是必要的， 个别计划项目中的拟议研究。 这些领域 包括建立和维护数据库， 所有血液制品输注的详细描述信息 以及所有ABO血型不合的 需要血浆修饰或骨髓红细胞的移植 耗尽